Cemdisiran: Clinical Trials

6 trials of Cemdisiran, newest first

ClinicalTrials Daily · Areas · Conditions · Drugs · Sponsors ·

3 recruiting, 2 active not recruiting, 1 terminated. 6 Phase 3.

By phase and status

Phase	Trials	Status
Phase 3	6	Recruiting 3, Active not recruiting 2, Terminated 1

Follow Cemdisiran: new trials by email Literature Review of Cemdisiran trials Research Report on Cemdisiran

Trials (filtered) newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
A Study to Evaluate How Pozelimab + Cemdisiran Combination Therapy Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Whose Current Treatment is Not Working Efficiently Pozelimab, Cemdisiran - Paroxysmal Nocturnal Hemoglobinuria	Phase 3	Recruiting	Regeneron Pharmaceuticals	35	2026-06-11	2026-08-05
A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy Pozelimab, Cemdisiran, Placebo - Age-related Macular Degeneration (AMD), Geographic Atrophy (GA)	Phase 3	Recruiting	Regeneron Pharmaceuticals	975	2024-10-30	2026-10-13
A Study in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) to Evaluate How Safe Long-term Treatment With Pozelimab + Cemdisiran Combination Therapy is and How Well it Works Pozelimab, Cemdisiran - Paroxysmal Nocturnal Hemoglobinuria	Phase 3	Recruiting	Regeneron Pharmaceuticals	202	2023-03-07	2026-09-28
Efficacy and Safety of the Combination of Pozelimab and Cemdisiran Versus Continued Eculizumab or Ravulizumab Treatment in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria Cemdisiran, Eculizumab, Pozelimab - Paroxysmal Nocturnal Hemoglobinuria	Phase 3	Terminated	Regeneron Pharmaceuticals	3	2022-10-06	2025-04-08
A Study to Evaluate How Safe Pozelimab + Cemdisiran Combination Therapy is and How Well it Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Not Recently Received or Have Not Received Complement Inhibitor Treatment Ravulizumab, Pozelimab, Cemdisiran - Paroxysmal Nocturnal Hemoglobinuria	Phase 3	Active not recruiting	Regeneron Pharmaceuticals	202	2022-08-01	2026-04-30
A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis Pozelimab + Cemdisiran, Cemdisiran, Placebo - Generalized Myasthenia Gravis	Phase 3	Active not recruiting	Regeneron Pharmaceuticals	288	2021-12-14	2026-10-28

Conditions studied

Sponsors

Countries

Results publications

NIH funding